Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti‐Obesity Medications: A Systematic Review, Meta‐Analysis and Meta‐Regression
Diabetes, Obesity and Metabolism · 2026-06 · 28 (6) · 4828-4836
DOI: 10.1111/dom.70667 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 16.03.2026. Verfasst von Muhammad Ahmed und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Obesity, Anti-Obesity Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
Background
Obesity is a complex chronic disease requiring effective long‐term management. We performed a systematic review and meta‐analysis to evaluate the efficacy and safety of cagrisema and cagrilintide monotherapy compared with semaglutide in individuals with obesity.
Methods
We searched MEDLINE, Embase, Scopus, Cochrane, and ClinicalTrials.gov for randomized controlled trials accessing cagrisema or cagrilintide versus semaglutide for weight loss. Efficacy outcomes were percentage change in body weight, absolute change in body weight, fasting plasma glucose, HbA1c, and BMI. Lipid parameters included total cholesterol, LDL‐C, HDL‐C, VLDL‐C, and triglycerides. A random‐effects model was used to estimate mean differences (MD) or risk ratios (RR) with 95% CIs.
Results
Three RCTs ( n = 3545) were included. Cagrisema produced significantly greater percentage [MD −7.47% (95% CI: −10.58, −4.36); p < 0.001] and absolute [MD −7.60 kg (95% CI: −10.33, −4.86); p < 0.001] weight loss than semaglutide. Cagrilintide monotherapy weight loss was comparable to semaglutide. Lipids parameters were mostly similar between groups, though LDL‐C was modestly higher with combination therapy versus semaglutide [MD 0.29 mmol/L (95% CI: 0.02, 0.55); p = 0.03]. Overall and serious adverse events were comparable between cagrisema and semaglutide, but combination therapy increased administration‐site conditions [RR 3.27 (95% CI: 1.27, 8.46)] and nausea [RR 1.64 (95% CI: 1.01, 2.66)]. Cagrilintide monotherapy had a higher risk of serious adverse events [RR 1.83 (95% CI: 1.03, 3.24)] compared to semaglutide.
Conclusion
Cagrisema is more effective than semaglutide in reducing weight and increasing glycemic control. Cagrisema is safe and has a comparable side effect profile to currently accepted treatments. This regimen has enormous potential in dual‐agonist therapy for obese patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
- Department of Medicine, Ziauddin Medical University, Karachi, Pakistan.
ORCID-Profile: Muhammad Ahmed, Muhammad Hassan, Saad Ahmed Waqas
Zitieren
APA
Ahmed, M., Hassan, M., Tahir, M., Hussain, M., Islam, F., Khan, G. T., Ahsan, M., Bin Shafiq, S., Ibrahim, A., Uddin, A., & Waqas, S. A. (2026). Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti‐Obesity Medications: A Systematic Review, Meta‐Analysis and Meta‐Regression. Diabetes, Obesity and Metabolism, 28(6), 4828-4836. https://doi.org/10.1111/dom.70667
Vancouver
Ahmed M, Hassan M, Tahir M, Hussain M, Islam F, Khan GT, et al. Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti‐Obesity Medications: A Systematic Review, Meta‐Analysis and Meta‐Regression. Diabetes, Obesity and Metabolism. 2026;28(6):4828-4836. doi:10.1111/dom.70667
BibTeX
@article{Ahmed2026,
author = {Ahmed, Muhammad and Hassan, Muhammad and Tahir, Muhammad and Hussain, Muhammad and Islam, Faisal and Khan, Ghulam Taha and Ahsan, Muhammad and Bin Shafiq, Shaheer and Ibrahim, Ahmed and Uddin, Ammad and Waqas, Saad Ahmed},
title = {Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti‐Obesity Medications: A Systematic Review, Meta‐Analysis and Meta‐Regression},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {6},
pages = {4828--4836},
doi = {10.1111/dom.70667}
}
EUVIMED